The Effect of Efavirenz on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy HIV-Negative Women
Antiviral Therapy2010Vol. 16(2), pp. 149–156
Citations Over TimeTop 10% of 2010 papers
Heather Sevinsky, Timothy Eley, Anna Persson, Dennis M. Garner, Cynthia Yones, Richard E. Nettles, Kathryn Krantz, Richard Bertz, Jenny Zhang
Abstract
Although efavirenz had no significant effect on the PK of EE, exposures to the progestin components of Ortho Cyclen, NGMN and LNG, were substantially reduced. The results reinforce the need to use reliable methods of barrier contraception, even when taking oral contraceptives and efavirenz.
Related Papers
- → Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor(2009)53 cited
- → Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy(2014)10 cited
- → Clinical Relevance of the Interaction When Switching Non-Nucleoside Reverse Transcriptase Inhibitors in Patients Infected with HIV(2014)2 cited
- → The Effects of Efavirenz and Rilpivirine on Lipids and Fat Distribution(2014)
- → COMPARING THE CARDIOVASCULAR RISK OF NORETHINDRONE ACETATE- AND LEVONORGESTREL-CONTAINING ORAL CONTRACEPTIVES: IS THERE A DIFFERENCE?(2020)